Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet age-related macular degeneration (AMD). Sustained dryness was defined as the beginning of three or more consecutive fluid-free (absence of both IRF and SRF) visits, as measured over 96 weeks. The analysis was presented at the virtual 2020 American Society of Retinal Specialists (ASRS) annual meeting.
In both trials, ≥50% of patients achieved sustained dryness faster with Beovu (by weeks 8 and 4 in HAWK and HARRIER, respectively, and by weeks 12 and 8 with aflibercept). Additionally, more than ≥75% of patients reached sustained dryness faster with Beovu than those treated with aflibercept (by weeks 32 and 20 with Beovu 3 mg and 6 mg in HAWK and HARRIER, respectively, and by weeks 56 and 52 with aflibercept 2 mg). Results also showed that following a 3-month loading phase, patients treated with Beovu required fewer injections to reach sustained retinal dryness, compared with aflibercept (an average of 3.3 and 2.6 injections with Beovu 3 mg and 6 mg in HAWK and HARRIER, respectively, and an average of 5.4 and 4.4 with aflibercept 2 mg).
“In wet AMD, drying retinal fluid effectively is a key goal of treatment, with the amount of fluid in the retina determining how often injections are needed. Frequent injections can place substantial burden on patients, leading to treatment drop-off,” Dirk Sauer, Development Unit Head, Novartis Ophthalmology, said in a company news release. “This analysis gives us further confidence in Beovu as a highly efficacious option for rapid and sustained fluid control.”
1 Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures. Available from: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. Accessed June 2020.